The long and winding road... getting Coartem® Dispersible to children

A new antimalarial is ready to be registered in a malaria-endemic country.

A1 LOCAL AGENT

B1 What happened in-country? A logistical hold-up meant the dossier didn’t reach the NDA.

B2 Novartis contacts MMV

B3 MMV’s help results in the drug being registered by the NDA in January 2010

B5 MMV and Novartis await news of the guidelines being updated

B6 Guidelines are updated

B7 Order for new drugs is delivered in November 2010

A2 The global or pharma company submits the drug dossier to the National Drug Authority (NDA) for registration

A3 WHO recommends the new drug to the National Malaria Control Programme (NMCP)

B8 MMV and Novartis work together with the NMCP to provide additional training for health workers

A4 MMV supports a meeting of the expert committee to review the guidelines

A5 New drug arrives in-country

A6 New drug is distributed to patients via the public sector

A7 Coartem® Dispersible is distributed to children via public sector channels